newest fda approved weight loss drug
Industry Insiders On Obesity Treatment's 2023 Turning Point
In 2023 the FDA cleared tirzepatide and an oral form of semaglutide for chronic weight management, giving clinicians two potent tools to combat obesity. These approvals moved GLP-1 based therapies from niche to frontline, prompting a surge in prescriptions and reshaping how patients and providers approach weight loss. Medical Disclaimer: